Biopharma pharmaceutical company intends to fulfill its annual production plan through large orders in the fourth quarter, co-owner of the company Kostiantyn Yefymenko has said during the presentation of the study “Portrait of a Ukrainian Entrepreneur” conducted by the Union of Ukrainian Entrepreneurs together with UMG with the support of Cipe.
“COVID-19 hit our business very seriously. We allocated UAH 15 million for humanitarian aid – we helped the Public Health Center and installed a laboratory for PCR and EIA diagnostics. We have already spent about UAH 10 million for the purchase of personal protective equipment and payment for our employees, work from home,” he said.
“Our business in April-June fell in total, I think, by 50%. After all, we produce hospital drugs. In Ukraine, virtually all operations except urgent ones were closed. We also suffered losses in a number of export regions. Now, since September, it is actually the first month our business has resumed, and we see large orders for the fourth quarter. In fact, for the fourth quarter we need to do what we did in six months and therefore we plan to fulfill the annual plans at our enterprises. The Tribo group of companies, I think, will lose 20% of proceeds in dollars. We are preparing for difficult times, preparing reserves,” the expert added.
In addition, Yefymenko noted that Biopharma plans to occupy 5% of the market for production of drugs from donor plasma in five years.
“We want to process one million liters of plasma within five years, we want to occupy 5% of the world market. Our mission is to bring the availability of protein therapy to developing countries. For this, we want to build plasma centers in at least four countries of the world as we are only in Ukraine now. If we are talking about plans for the next ten years, we have a task to build two more plants on two continents. To occupy about 10-12% of the world market and from 13 companies that are engaged in fractionation of blood plasma in the world (the company ranks 12th), we want to enter the seven, that is, we must be a company with a turnover of at least $750 million,” he said.
